SMMT Inks Deal With AZN-Daiichi to Study Ivonescimab + Datroway CombosZacks Investment Research • 10/05/26
Daiichi Sankyo and AstraZeneca Enter into Clinical Trial Collaboration with Summit Therapeutics to Evaluate Datroway® in Combination with Ivonescimab Across Multiple Tumor TypesBusiness Wire • 10/02/26
Summit Therapeutics Announces Clinical Trial Collaboration with AstraZeneca and Daiichi Sankyo to Evaluate Ivonescimab in Combination with TROP2-Directed ADC DatrowayBusiness Wire • 10/02/26
AstraZeneca's $2 Billion Vote of Confidence Leaves Summit Therapeutics Trading Well Below Street Targets24/7 Wall Street • 09/30/26
Astrazeneca (AZN) Registers a Bigger Fall Than the Market: Important Facts to NoteZacks Investment Research • 09/29/26
AstraZeneca Digs $2 Billion Out Of Its Coffers For Summit Deal, Taking On Bristol, Pfizer, MerckInvestors Business Daily • 09/29/26
AstraZeneca's $2 billion Summit stake wins backing from UBS and JefferiesProactive Investors • 09/29/26
AstraZeneca invests $2 billion in Summit Therapeutics in cancer drug dealProactive Investors • 09/29/26
Anthropic warns of ‘existential risks to humanity' from AI; AstraZeneca makes $2bn cancer drug tie-up – business liveThe Guardian • 09/29/26
AstraZeneca Makes $2 Billion Strategic Equity Investment in Summit TherapeuticsBusiness Wire • 09/28/26
Eccogene Receives $50 Million Milestone Payment from AstraZeneca Following Initiation of Global Phase 3 Program for Elecoglipron (AZD5004/ECC5004)Business Wire • 09/28/26
Is AstraZeneca's Oncology Portfolio Positioned for Continued Growth?Zacks Investment Research • 09/28/26
Perioperative IMFINZI® (durvalumab) plus neoadjuvant enfortumab vedotin granted Priority Review in the US for patients with muscle-invasive bladder cancerBusiness Wire • 09/25/26